Tetsuya Suhara

Active 1991–2025

151
Papers
20,704
Citations
82
h-index
145
i10-index

Citations

Citations per year for Tetsuya Suhara1978: 1 citations1980: 1 citations1992: 1 citations1993: 3 citations1994: 5 citations1995: 6 citations1996: 8 citations1997: 24 citations1998: 22 citations1999: 40 citations2000: 36 citations2001: 42 citations2002: 63 citations2003: 66 citations2004: 68 citations2005: 79 citations2006: 124 citations2007: 203 citations2008: 295 citations2009: 290 citations2010: 275 citations2011: 257 citations2012: 294 citations2013: 240 citations2014: 300 citations2015: 248 citations2016: 266 citations2017: 291 citations2018: 227 citations2019: 535 citations2020: 692 citations2021: 642 citations2022: 557 citations2023: 394 citations2024: 525 citations2025: 252 citations2026: 10 citations1979: no citations, so this year is not shown1981–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,600 citing papers, 29.2% of this breakdownUnited Kingdom: 760 citing papers, 8.6% of this breakdownJapan: 591 citing papers, 6.7% of this breakdownGermany: 577 citing papers, 6.5% of this breakdownChina: 497 citing papers, 5.6% of this breakdownCanada: 474 citing papers, 5.3% of this breakdownSweden: 332 citing papers, 3.7% of this breakdownFrance: 288 citing papers, 3.2% of this breakdownAustralia: 278 citing papers, 3.1% of this breakdownItaly: 267 citing papers, 3% of this breakdownNetherlands: 246 citing papers, 2.8% of this breakdownSwitzerland: 215 citing papers, 2.4% of this breakdown
0%29.2%Other 19.9%

Fields

  • Medicine47.6%
  • Neuroscience33.7%
  • Biochemistry, Genetics and Molecular Biology9.3%
  • Psychology4%
  • Materials Science1%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Other3.6%

Topics

  • Alzheimer's disease research and treatments10.1%
  • Neuroscience and Neuropharmacology Research5.4%
  • Neuroinflammation and Neurodegeneration Mechanisms5.2%
  • Neurotransmitter Receptor Influence on Behavior4.2%
  • Functional Brain Connectivity Studies3.5%
  • Parkinson's Disease Mechanisms and Treatments3.1%
  • Other68.5%

Coauthors

All papers

Open in search
  1. Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model

    Authors: , , , , , , , , , - Neuron 2007 cited by 2,275

  2. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Cerebral Blood Flow & Metabolism 2007 cited by 1,985

  3. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Masanori Ichise, Yutaka Tomita, Ming‐Rong Zhang, Tetsuya Suhara, Masahiro Shigeta, Naruhiko Sahara, Makoto Higuchi, Hitoshi Shimada - Neuron 2020 cited by 268

  4. P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating

    Authors: , , , , , , , , , , , , - PLoS ONE 2011 cited by 251

  5. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Neuron 2013 cited by 772

  6. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET

    Authors: , , , , , , , , , , , , - Neurology 2009 cited by 367

  7. High‐Contrast Imaging of α‐Synuclein Pathologies in Living Patients with Multiple System Atrophy

    Authors: , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2022 cited by 59

  8. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies

    Authors: , , , , , , , , , , , , , , , , - Brain 2016 cited by 207

  9. Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy

    Authors: , , , , , , , , , , , , , - Aging Cell 2022 cited by 46

  10. Linearized Reference Tissue Parametric Imaging Methods: Application to [ 11 C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain

    Authors: , , , , , , , , , - Journal of Cerebral Blood Flow & Metabolism 2003 cited by 677

  11. Selective Disruption of Inhibitory Synapses Leading to Neuronal Hyperexcitability at an Early Stage of Tau Pathogenesis in a Mouse Model

    Authors: , , , , , , , , , , , , , , , , - Journal of Neuroscience 2020 cited by 91

  12. Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor

    Authors: , , , , , , , , , , , , , , , , , , , , - Brain Communications 2021 cited by 82

  13. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

    Authors: , , , , , , , , , , , , - Nature 1997 cited by 719

  14. Pharmacokinetics and brain uptake of lactoferrin in rats

    Authors: , , , , , , - Life Sciences 2005 cited by 165

  15. Chemogenetic dissection of the primate prefronto-subcortical pathways for working memory and decision-making

    Authors: , , , , , , , , , , - Science Advances 2021 cited by 67

  16. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease

    Authors: , , , , , , , , , - Journal of Neurology 2019 cited by 61

  17. Regulation of Anxiety and Depression by Mitochondrial Translocator Protein-Mediated Steroidogenesis: the Role of Neurons

    Authors: , , , , , - Molecular Neurobiology 2020 cited by 43

  18. Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants

    Authors: , , , , , , , , , , , , , , , , , , , - Scientific Reports 2020 cited by 74

  19. PET imaging of colony-stimulating factor 1 receptor: A head-to-head comparison of a novel radioligand, 11 C-GW2580, and 11 C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey

    Authors: , , , , , , , , , , , - Journal of Cerebral Blood Flow & Metabolism 2021 cited by 63

  20. Deficiency of Schnurri-2, an MHC Enhancer Binding Protein, Induces Mild Chronic Inflammation in the Brain and Confers Molecular, Neuronal, and Behavioral Phenotypes Related to Schizophrenia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuropsychopharmacology 2013 cited by 173

  21. Differential Contributions of Prefrontal and Hippocampal Dopamine D1and D2Receptors in Human Cognitive Functions

    Authors: , , , , , , , , , , - Journal of Neuroscience 2008 cited by 168

  22. Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2012 cited by 124

  23. Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons

    Authors: , , , , , , , , , , , , , , , , , - Scientific Reports 2016 cited by 82

  24. Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models

    Authors: , , , , , , , , - Journal of Nuclear Medicine 2018 cited by 81